Navigation Links
Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet
Date:7/7/2009

LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical cancer vaccine is published today in The Lancet. The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix(R) is highly effective at protecting against the two most common cervical cancer-causing human papillomavirus (HPV) types, 16 and 18. The study also showed that the vaccine provides cross-protection against HPV types 31, 33 and 45, the three most common cancer-causing virus types beyond 16 and 18.

Thomas Breuer, Head of Global Clinical R&D and Chief Medical Officer of GSK Biologicals commented: "These excellent study results confirm the efficacy offered by Cervarix(R) against HPV 16 and 18. For the first time the results show that this vaccine was effective against cervical pre-cancers associated with the five most common cancer-causing virus types. This is really good news for primary prevention of cervical cancer as it indicates the vaccine could offer women additional protection against cervical cancer beyond what had at first been anticipated."

The study showed that in women who complied with the trial protocol procedures (87% of the total sample), the vaccine provided 92.9 percent protection against cervical pre-cancers (cervical intraepithelial neoplasia 2+ or CIN 2+) associated with HPV 16 or 18. A further analysis of the same cohort which excluded lesions not likely to be caused by HPV 16 and 18 revealed that the vaccine was 98.1 percent effective against cervical pre-cancers (CIN 2+) caused by these two types.

The study showed -- for the first time for any cervical cancer vaccine -- that Cervarix(R) provided significant cross-protection against pre-cancerous lesions not containing HPV types 16 and/or 18. This additional efficacy could translate into approximately 11-16 percent extra protection against cervical cancer over and above the protection afforded
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
2. Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap
3. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
4. New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
5. Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkins Lymphoma
6. Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing
7. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
8. Established Safety Profile of Spiriva Confirmed by 30 Rigorously Controlled Clinical Trials and the Landmark Trial UPLIFT
9. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
10. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
11. TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... HILLSBORO, Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- ... and a targeting guide with accompanying instrumentation to place ... new adjunct to the soft tissue (e.g. ligament) repair ... soft tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ...
(Date:1/14/2014)... a manufacturer of ergonomically designed laboratory equipment for research, ... Japan to sell and service the Hitachi brand ... utilize its network of sales professionals throughout the United ... assistance in application use, product benefits and features, options and accessories, ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a privately ... for Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of January 15, ... at New York Medical College. Oligomerix, which ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... Eisai Corporation of North America today announced that the ... review the company,s supplemental new drug application (sNDA) for ... injection) to treat patients with myelodysplastic syndromes (MDS). ... diseases that limit the production of functional blood cells. ...
... Amgen (Nasdaq: AMGN ) today announced that ... Zometa(R) (zoledronic acid) in the treatment of bone metastases ... primary and secondary endpoints and demonstrated superior efficacy compared ... the time to the first on-study Skeletal Related Events ...
Cached Medicine Technology:FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS) 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:4/23/2014)... a country as wealthy as the United States, it may ... not have access to adequate food due to lack of ... , Recent research at the University of Illinois using data ... that the seniors who are dealing with hunger are also ... 8.35 percent of Americans over age 60 faced the threat ...
(Date:4/23/2014)... PROVIDENCE, R.I. Parents and physicians concerned about an ... medical marijuana can breathe a sigh of relief. According ... compared 20 years worth of data from states with ... not lead to increased use among adolescents. The study ... Journal of Adolescent Health . , "Any ...
(Date:4/23/2014)... depletion of self-control, according to research published in ... Psychological Science. , Self-control can be difficult sticking ... a boring textbook are hard things to do. Considerable ... self-control for a long period seems to "deplete" our ... "It is as if self-control is a limited resource ...
(Date:4/22/2014)... a popular high school sport in the United States ... by researchers in the Center for Injury Research and ... compare and describe the occurrence and distribution patterns of ... school athletic training setting among adolescents and teens. , ... Athletic Training , examined data relating to adolescents 13-19 ...
(Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
Breaking Medicine News(10 mins):Health News:More Americans in their golden years are going hungry 2Health News:RI Hospital physician: Legalizing medical marijuana doesn't increase use among adolescents 2Health News:ADHD drug may help preserve our self-control resources 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... Pa., June 1 Practice-Reps, LLC ( http://www.practice-reps.com ) ... to specialty medical practices along the East Coast. The ... a 16-year veteran of the practice marketing industry, to ... experienced marketing support on a part-time basis. , ...
... SAN FRANCISCO, Calif., June 1 Rigel Pharmaceuticals, Inc. ... oral Syk inhibitor, R788, is being evaluated in a ... the National Cancer Institute (NCI), part of the U.S. ... trial will include patients with advanced colorectal, thyroid, non-small ...
... , Collaboration Delivers Cost and Quality Benefits for Widespread ... June 1 SAFC(R) ( www.safcglobal.com ), a member ... and Cherokee Pharmaceuticals(TM) ( www.cherokee-pharma.com ... business, today announced an exclusive strategic partnership that encompasses ...
... , New Product Names for Recently Introduced MicroRNA-based Diagnostics ... Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic ... platform yesterday at the American Society of Clinical Oncology ... a presentation entitled "Profiling of Receptor Tyrosine Kinases (RTK) ...
... the mouth and periodontists to ask questions about heart health ... leading killer of men and women in the United States, ... each day. Periodontal disease, a chronic inflammatory disease that destroys ... 75 percent of Americans and is the major cause of ...
... program aimed at reducing criminal behavior in juvenile justice teens ... reducing the teens, rate of pregnancy, according to a new ... in the Department of Psychology at Oregon State University, and ... Learning Center, conducted the research, which will be published in ...
Cached Medicine News:Health News:Practice-Reps Brings Sales and Marketing to the Business of Medical Practice Management 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 2Health News:Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers 3Health News:SAFC(R) & Cherokee Pharmaceuticals(TM) Pool Expertise and Resources With Strategic Partnership For U.S. Market 2Health News:SAFC(R) & Cherokee Pharmaceuticals(TM) Pool Expertise and Resources With Strategic Partnership For U.S. Market 3Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 2Health News:Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 2Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 3Health News:Healthy Gums and a Healthy Heart: The Perio-Cardio Connection 4Health News:Intervention reduces delinquent teenage pregancy rates 2Health News:Intervention reduces delinquent teenage pregancy rates 3
Three-spring evacuator kits with silicone drains, 10 in. hole pattern, trocar and Y-connector tubing...
Reliavac® 400cc kits with silicone round drain with 10 in. hole pattern, trocar, and Y-connector tubing...
Reliavac 100cc evacuators offer a more constant suction profile than silicone evacuators. 100cc capacity is easy for patient to carry. Bottom emptying port reduces chance of contamination....
Used in the peritoneal cavity to remove large volumes of thick exudate....
Medicine Products: